Altria Group (MO) — Company Research

Last Updated: 12 November 2026

Altria Group is the parent of Philip Morris USA, maker of Marlboro, the best-selling cigarette brand in the United States, along with U.S. Smokeless Tobacco (Copenhagen, Skoal), Helix (on! nicotine pouches) and NJOY (e-vapor). It is one of the highest-yielding large caps in the S&P 500, returning most of its cash flow through dividends while trying to grow smoke-free products against steady cigarette volume declines. This report covers the latest filings, including the Q3 2026 results released on 29 Oct 2026. Follow price action on our Live Charts, check macro events on the Economic Calendar, and discuss the stock in the ChartsView Forum.

1. Company Snapshot

2. Bull Case vs Bear Case

Bull Case

• Pricing power on Marlboro: Smokeable adjusted OCI margin was 64.5% in Q3 2026 even with domestic cigarette shipments down 2.9%, showing price increases still more than offset volume declines.
• Cash return machine: FY2025 operating cash flow of $9,290m against capex of $216m funds roughly $7bn a year of dividends, with mid-single-digit dividend growth targeted through 2028.
• on! pouches gaining ground: on! shipments rose 13.3% in Q3 2026 to 47.8m cans, and FDA marketing orders for on! PLUS (Dec 2025) and new on! flavours (Aug 2026) widen the authorised range.
• Guidance moving up: 2026 adjusted EPS guidance was raised to $5.66 to $5.74 (+4.5% to +6.0%) on 29 Oct 2026, alongside a $1bn buyback expansion running to 31 Dec 2027.

Bear Case

• Structural volume decline: Domestic cigarette shipments fell 10.0% in FY2025 and Marlboro shipments are down 7.2% year to date in 2026, with discount brands taking share (34.1% industry discount share in Q3 2026).
• Smoke-free strategy setbacks: NJOY ACE has been off the US market since the ITC exclusion order took effect on 31 Mar 2025, and FY2025 included about $2.1bn of e-vapor impairments.
• Oral share erosion: Altria's share of the oral category fell to 28.6% from 32.5%, as Copenhagen and Skoal decline faster than on! grows.
• Thin balance-sheet cushion: Total debt of $24.1bn and a stockholders' deficit of $(2.2)bn at 30 Sep 2026 leave dividend growth dependent on continued cigarette pricing.

3. Segments & Revenue Mix

For FY2025 Altria reported smokeable products, oral tobacco products and e-vapor (NJOY) as segments; in 2026 releases NJOY has moved back into "all other", leaving smokeable and oral as the reportable segments. Percentages below are of FY2025 revenues net of excise taxes ($20,139m).

Altria also holds an equity-accounted stake of about 8.1% in Anheuser-Busch InBev (30 Sep 2026), down from 8.2% through dilution rather than any share sales, and a 75% interest in Horizon, its US heated-tobacco joint venture with Japan Tobacco.

4. Business Model & Moat

How it makes money. Altria buys leaf tobacco, manufactures cigarettes, cigars and oral products in the US, and sells them to wholesalers and retailers. Because US cigarette volumes fall each year, revenue is held up by regular list-price increases on Marlboro and other brands. Excise taxes are billed to customers and passed through, which is why the company reports revenues both including and net of excise.

Where the moat comes from. Marlboro had a 40.5% US retail share in FY2025 and 60.0% of the premium segment in Q3 2026. Tight marketing restrictions and the FDA's premarket review rules make it very hard for new entrants to build brands, and Altria's US distribution reach is a further barrier. These factors support adjusted OCI margins of 62.4% across the company in FY2025.

Capital allocation. Management targets debt-to-EBITDA of about 2.0x (2.0x at end-2025), mid-single-digit annual dividend-per-share growth through 2028, and uses buybacks with the remaining cash. The Optimize & Accelerate initiative targets at least $600m of cost savings by 2029.

Where the moat is weaker. In newer categories, brand loyalty and regulation protect Altria less: illicit flavoured disposable vapes have taken share, and patent litigation with JUUL removed NJOY ACE from shelves.

5. Financial Health

Annual figures from Altria's 10-K filings and Q4 earnings releases. Revenue is revenues net of excise taxes.

† From Q1 2025 Altria's adjusted EPS excludes amortisation of intangibles; FY2024 is shown on the recast basis ($5.12 as originally reported). FY2021 to FY2023 are as originally reported. Long-term debt includes the current portion (FY2025: $24,140m noncurrent plus $1,569m current), per SEC XBRL data. FY2025 GAAP EPS includes about $2.1bn of e-vapor impairments.

Quarterly results, most recent first (net revenues include excise taxes, as headlined by the company).

Cash flow and balance sheet. FY2025 operating cash flow was $9,290m, capex $216m and depreciation and amortisation $266m; nine-month 2026 operating cash flow was $6,151m. At 30 Sep 2026 total debt was $24,061m ($22,886m noncurrent plus $1,175m current) and cash was $2,697m, with no short-term borrowings. Altria paid $5.3bn of dividends and repurchased 11.2m shares for $735m in the first nine months of 2026. The $3.0bn revolving credit facility was extended to 24 Oct 2030.

6. Valuation Snapshot

Raw metrics, November 2026. Not opinions on whether the stock is cheap or expensive.

7. What Are They Building

• Nicotine pouches: on! PLUS received FDA marketing orders in Dec 2025 for tobacco, mint and wintergreen at 6mg and 9mg, and applications for six more flavours were filed in Nov 2025. The original on! line received orders in Aug 2026 for autumn spice, rich berry and cappuccino. New flavours (Blueberry Mint, Mango Pineapple, and Watermelon Mint from Q4 2026) are rolling out.
• Heated tobacco (Horizon): Altria's 75%-owned joint venture with Japan Tobacco plans to sell Ploom devices with Marlboro heated-tobacco sticks once FDA authorisation is received; no product was on sale at 30 Sep 2026.
• NJOY e-vapor: NJOY ACE is barred by the ITC order while Altria's Federal Circuit appeal is pending. A second JUUL ITC case goes to hearing in Feb 2027. Up to $250m of contingent payments remain tied to FDA authorisation of ACE flavoured pods.
• Manufacturing: U.S. Smokeless Tobacco broke ground on a $250m facility in Hopkinsville, Kentucky on 08 Sep 2026, consolidating Nashville operations by Q1 2028. Under an Aug 2026 agreement, PM USA will manufacture cigarettes for Philip Morris International's non-US affiliates, with first shipments in early 2027.
• 2028 enterprise goals: mid-single-digit adjusted EPS CAGR from a 2022 base of $4.87, adjusted OCI margin of at least 60%, at least five non-nicotine products in broad distribution, and international expansion in oral nicotine (on! in Sweden and the UK). Smoke-free volume goals are being reassessed because of illicit vapes.

8. Competitive Landscape

Altria competes in the US mainly on brand and price. In nicotine pouches, on! held 13.5% of the US pouch category in Q3 2026, and pouches made up 61.2% of the oral category.

9. Insider Activity

Sal Mancuso has been CEO since 14 May 2026. The table lists 2026 Form 4 transactions excluding award grants. None of the filings has the Rule 10b5-1 box ticked.

Source: SEC Form 4 filings for CIK 764180. Mancuso also received a CEO grant of 40,634 restricted stock units on 13 May 2026.

10. Key Risks

• Regulatory: The FDA proposed a maximum-nicotine standard for cigarettes and most cigars in Jan 2025, and the proposed menthol and flavoured-cigar bans were returned to the FDA rather than withdrawn. Either could reshape the smokeable business, which earns about 87% of revenue.
• Volume decline: Industry cigarette volumes are falling about 5% a year, and shifts to discount brands put Marlboro pricing at risk if consumers' disposable income tightens.
• Illicit e-vapor: Unauthorised flavoured disposable vapes have taken share from both cigarettes and NJOY, and the 10-Q describes enforcement as gradual.
• Litigation: Smoking-and-health cases (including Engle progeny) cost $120m pre-tax in 9M 2026, and the JUUL patent fight keeps NJOY ACE off the market.
• Balance sheet: $24.1bn of debt and a stockholders' deficit mean dividends of about $7bn a year absorb most operating cash flow, leaving little room if earnings fall.
• Impairments and investments: FY2025 included about $2.1bn of e-vapor impairments; the ABI stake and Cronos investment carry further write-down risk.

11. Recent Developments

• 29 Oct 2026 — Q3 results and guidance raised. Net revenues rose 1.0% to $6,132m and adjusted EPS rose 4.8% to $1.52. 2026 adjusted EPS guidance was raised to $5.66 to $5.74 and the board added $1bn to the buyback, which now runs to 31 Dec 2027.
• 08 Oct 2026 — FDA lawsuit stayed. A Texas federal court paused the Helix and NJOY challenge to the FDA's premarket application rules while the agency writes a new rule.
• 07 Oct 2026 — Credit facility extended. Altria extended its $3.0bn revolving credit facility to 24 Oct 2030.
• 09 Sep 2026 — Chair buys shares. Board Chair Kathryn McQuade bought 1,500 shares at $67.62, the only open-market insider purchase of 2026.
• 08 Sep 2026 — Kentucky facility. U.S. Smokeless Tobacco broke ground on a $250m plant in Hopkinsville, adding more than 200 jobs.
• 02 Sep 2026 — Helix and NJOY sue the FDA. The subsidiaries challenged the 2021 premarket application rule and the FDA's 180-day review deadlines.
• 27 Aug 2026 — Dividend raised. The quarterly dividend rose 4.7% to $1.11 per share, paid 09 Oct 2026.

12. Key Dates

• 24 Nov 2026 — Next FINRA short-interest release (13 Nov settlement).
• Expected Dec 2026 — Declaration of the next quarterly dividend (last year declared 10 Dec, paid 09 Jan).
• Expected Jan 2027 — Q4 and FY2026 results with 2027 guidance; date not yet confirmed (FY2025 results were released 29 Jan 2026).
• Expected Feb 2027 — Evidentiary hearing in JUUL's second ITC case against NJOY.
• Expected May 2027 — 2027 annual shareholder meeting (date TBC; the 2026 meeting was 14 May).
• Expected Jul 2027 — ITC initial determination in the second JUUL case; final determination expected Nov 2027.
• 31 Dec 2027 — Expiry of the expanded share repurchase programme.

No date has been given for the Federal Circuit ruling on the NJOY ACE appeal or for an FDA decision on the Horizon heated-tobacco application.

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.